Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Finished Goods: 2023-2025

Historic Finished Goods for Catalyst Pharmaceuticals (CPRX) over the last 2 years, with Sep 2025 value amounting to $11.3 million.

  • Catalyst Pharmaceuticals' Finished Goods rose 22.17% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year increase of 22.17%. This contributed to the annual value of $9.6 million for FY2024, which is 4.55% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Finished Goods is $11.3 million, which was up 39.08% from $8.1 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Finished Goods peaked at $11.3 million during Q3 2025, and registered a low of $8.1 million during Q1 2025.
  • For the 3-year period, Catalyst Pharmaceuticals' Finished Goods averaged around $9.1 million, with its median value being $9.2 million (2023).
  • Data for Catalyst Pharmaceuticals' Finished Goods shows a peak YoY increase of 22.17% (in 2025) and a maximum YoY decrease of 3.29% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Catalyst Pharmaceuticals' Finished Goods stood at $9.2 million in 2023, then climbed by 4.55% to $9.6 million in 2024, then grew by 22.17% to $11.3 million in 2025.
  • Its last three reported values are $11.3 million in Q3 2025, $8.1 million for Q2 2025, and $8.1 million during Q1 2025.